EZH2 overexpression is associated with poor GBM prognosis, and reducing levels of EZH2 expression in vivo resulted in a reduced tumor progression, which suggests the efficacy of EZH2 inhibitors as anti-glioma therapies (286, 287). The gene discussed is EZH2; the disease is glioblastoma.